FEIBA is trusted and has a proven safety profile

  • FEIBA is approved in over 60 countries worldwide2,3
  • Physicians have been using FEIBA successfully for more than 35 years2,3

Documented Pathogen Safety Profile

  • To date,** no confirmed spontaneous reports of hepatitis A, B, and C or HIV transmission have been received that can be definitively linked to FEIBA VH and/or NF administration2

*Validated as of September 2012

Important Safety Information

FEIBA must not be used in the following situations if therapeutic alternatives to FEIBA are available:

  • Hypersensitivity to the product or any of the components.
  • Disseminated Intravascular Coagulation (DIC).
  • Acute thrombosis or embolism (including myocardial infarction).

Thrombotic and thromboembolic events, including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke have occurred in the course of treatment with FEIBA, particularly after administration of doses above the maximum daily dose and/or prolonged application or in patients with other risk factors for thromboembolic events.
As with any intravenously administered plasma product, allergic type hypersensitivity reactions may occur; patients should be informed of the early signs of hypersensitivity reactions. When medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.
Administration of FEIBA to patients with inhibitors may result in an initial anamnestic rise in inhibitor levels. Upon continued administration of FEIBA, inhibitors may decrease over time. Clinical and published data suggest that the efficacy of FEIBA is not reduced.

References

  1. 1. Data on file. Baxter Healthcare Corp, Westlake Village, USA.
  2. 2. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia. 2004;20(suppl 2):10-16.
  3. 3. FEIBA Summary of Product Characteristics 2010.

Prescribing FEIBA

Find out how to use FEIBA and gain insights into managing your patients effectively. Read more

Publications

Access articles related to managing haemophilia patients with inhibitors. Read more

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more